Diffuse large B-cell lymphoma trials in Japan

In Japan 8 Also abroad 346

8 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
Where
Bunkyo, Chiba, Chūō, Fukuoka, Hiroshima, Iruma-gun, Isehara, Kanazawa, Kashiwa, Kobe, Kyoto, Matsuyama, Miyazaki, Nagoya, Okayama, Osaka, Sakai, Sendai, Yamagata
Age
18 years and over
People
1,046 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06717347 · EU 2024-515566-13-00
Phase 1Taking people
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Where
Chiba, Okayama, Tokyo
Age
18 years and over
People
460 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07226843 · EU 2025-523601-16-00
Phase 2/3Taking people
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
Where
Bunkyo, Chūō, Fukuoka, Fukushima, Hirakata, Isehara, Kyoto, Minato, Miyazaki, Osaka, Sapporo, Tsu, Yamagata
Age
18 years and over
People
290 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT05139017 · EU 2022-502646-27-00
Phase 2Taking people
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
Where
Bunkyo, Chūō, Hirakata, Izumo, Nagasaki, Nagoya, Sapporo, Sendai, Toyoake
Age
18 years and over
People
594 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06890884 · EU 2024-515526-89-00
Phase 1Taking people
A Study of Mevrometostat for Treatment of Relapsed/Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma
Where
Kashiwa
Age
18 years and over
People
453 worldwide
Run by
Pfizer
See details and how to joinNCT03460977 · EU 2023-509179-18-00
Phase 1/2Taking people
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
Where
Chiba, Kashiwa, Kōtoku, Nagoya, Yokohama
Age
18 years and over
People
689 worldwide
Run by
BeOne Medicines
See details and how to joinNCT05006716 · EU 2022-502157-33-00
Phase 3Taking people
Study of Out of Specification for Tisagenlecleucel
Where
Aomori, Bunkyo Ku, Chiba, Chuo Ku, Fuchū, Fukuoka, Gifu, Hamamatsu, Hiroshima, Ishikawa, Izumi, Izumisano, Izumo, Kita-gun, Kobe, Kumamoto, Kurashiki, Kyoto, Matsumoto, Minato Ku, Nagasaki, Nagoya, Niigata, Nishinomiya, Okayama, Osaka, Saitama, Sakai, Sapporo, Sendai, Setagaya-ku, Shinjuku Ku, Suita, Tōon, Tsu, Tsukuba, Wakayama, Yokohama, Yufu
Age
0 years to 100 years
People
200 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT04094311
Phase 2Taking people
DALY II Japan/MB-CART2019.1 for DLBCL
Where
Tokyo
Age
18 years and over
People
31
Run by
Miltenyi Biomedicine GmbH
See details and how to joinNCT07288879